Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

November 2021; 8 (6) Clinical/Scientific NotesOpen Access

Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors

Alberto Picca, Nefeli Valyraki, Cristina Birzu, Nora Kramkimel, Olivier Hermine, Noel Zahr, Giulia Berzero, Dimitri Psimaras
First published September 8, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001073
Alberto Picca
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: picca.alberto@gmail.com
Nefeli Valyraki
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nef.val92@gmail.com
Cristina Birzu
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cristina.birzu89@yahoo.com
Nora Kramkimel
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nora.kramkimel@aphp.fr
Olivier Hermine
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ohermine@gmail.com
Noel Zahr
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
PharmD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: noel.zahr@aphp.fr
Giulia Berzero
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giulia.berzero01@universitadipavia.it
Dimitri Psimaras
From the AP-HP (A.P., N.V., C.B., G.B., D.P.), GH Pitié-Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France; AP-HP (N.K.), Hôpital Cochin, Department of Dermatology, Paris, France; AP-HP (O.H.), Hôpital Necker, Department of Haematology, Imagine Institute, INSERM U1163, University of Paris, France; AP-HP (N.Z.), GH Pitié-Salpêtrière, Department of Pharmacology, Paris, France; Neurology Unit (G.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and OncoNeuroTox Group (D.P.), Center for Patients with Neurological Complications of Oncologic Treatments, GH Pitié-Salpetrière et Hôpital Percy, Paris, France.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Alberto Picca, Nefeli Valyraki, Cristina Birzu, Nora Kramkimel, Olivier Hermine, Noel Zahr, Giulia Berzero, Dimitri Psimaras
Neurol Neuroimmunol Neuroinflamm Nov 2021, 8 (6) e1073; DOI: 10.1212/NXI.0000000000001073

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
850

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background and Objectives To describe the marked clinical and biological responses of a targeted treatment with anti–interleukin-6 (IL-6)–receptor antibody and Janus kinase (JAK) inhibitors in a patient with a severe, corticoresistant CNS toxicity of immune-checkpoint inhibitor (ICI) therapy.

Methods A 58-year-old man was admitted for subacute paraparesis, urinary retention, and ascending paresthesia. He was under treatment with ipilimumab and nivolumab for metastatic melanoma. Spine MRI disclosed multiple T2-hyperintense, contrast-enhancing longitudinally extensive lesions. A diagnosis of ICI-related acute transverse myelitis was made.

Results ICIs were immediately discontinued, and the patient received high-dose glucocorticoids plus 1 session of plasma exchange, but he did not improve. Based on the marked elevation of CSF IL-6 (505 pg/mL), a second-line targeted therapy with anti-IL-6-receptor tocilizumab (8 mg/kg/mo for 3 infusions) plus JAK inhibitor ruxolitinib (50 mg/d) was administered. Patient neurologic status started to improve shortly after, with corresponding radiologic resolution. At 9 months, the patient was able to walk independently, presenting only slight residual disability while remaining in oncologic partial response.

Discussion Our case suggests that some patients with severe, corticoresistant CNS immune-related toxicities of ICIs may benefit from cytokine blockade. Cytokine measurement in serum and CSF might help in selecting patients for personalized treatment strategies.

Neurologic immune-related adverse events (irAEs) of immune-checkpoint inhibitors (ICIs) are uncommon but often severe and potentially life-threatening. High-dose glucocorticoids may be insufficient,1 but optimal treatment in severe and refractory cases remains to be defined.

In this study, we report the case of a 58-year-old man who started combined treatment with ipilimumab and nivolumab for BRAF–wild-type metastatic melanoma. After the fourth ICI cycle, the patient presented with rapidly progressing paraparesis, urinary retention, and ascending paresthesia, which peaked in 10 days from onset. Neurologic examination showed severe flaccid paraparesis, a dorsal sensory level (T10) with impaired proprioception, and absent deep tendon reflexes. Spine MRI disclosed multiple T2 hyperintensities at C2, C3, C7-T2, T4-T7, and T8-conus levels with associated patchy contrast enhancement (Figure 1, B and C). CSF analysis displayed increased proteins (2.57 g/L) and cell count (112/mm3) with no malignant cells. Screening for anti-aquaporin-4, anti-myelin oligodendrocyte glycoprotein, anti-glutamic acid decarboxylase, and onconeural antibodies (including anti-Hu, anti-Ri, anti-CV2, and anti-amphiphysin) was negative. Cytokine assessment showed a marked elevation of interleukin-6 (IL-6) in the CSF (505 pg/mL, upper normal limit 4 pg/mL) (Figure 1A). After excluding alternative infectious, vascular, and neoplastic causes, a diagnosis of ICI-related acute transverse myelitis was made.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Imaging, Treatment, CSF Monitoring, and Functional Outcome in a Patient With Severe ICI-Related Myelitis

(A) Timeline of patient functional status (as expressed by the modified Rankin Scale [mRS], gray curve), IL-6 levels in CSF (orange dots) and serum (blue dots), and administered treatments. The first CSF analysis at day 10 from symptom onset displayed an inflammatory CSF with markedly increased IL-6 level (515 pg/mL) that rapidly decreased after the first administration of tocilizumab and introduction of oral ruxolitinib (8 pg/mL at day 29 and indetectable at day 50). Follow-up CSF analysis at 3 months (day 107) disclosed a slight rise in CSF inflammatory markers (CSF IL-6: 6 pg/mL; CSF proteins: 1.8 g/L; and CSF cells: 17/mm3) that justified a third administration of IV tocilizumab despite the sustained clinical and radiological improvement. (B and C) Lumbosacral spine MRI at diagnosis displayed a longitudinally extensive lesion with spinal swelling from T8 to the conus in T2-weighted sequences (T2w) (B), with an associated faint parenchymal and leptomeningeal enhancement in postgadolinium T1-weighted images (T1w-Gd) (C). (D and E) Lumbosacral spine MRI 1 week after the introduction of tocilizumab and ruxolitinib, showing a marked reduction of the spinal hyperintensities in T2-weighted images (D) and resolution of the contrast enhancement in postgadolinium T1-weighted images (E). ICI = immune-checkpoint inhibitor; IL-6 = interleukin-6; IVMP = intravenous methylprednisolone; PLEX = plasma exchange; Toci = tocilizumab.

ICIs were immediately discontinued, and the patient received IV methylprednisolone (3.5 g over 4 days), followed by oral prednisone tapering (from 100 mg/d) and 1 session of plasma exchange to remove residual circulating ICIs, but the patient did not improve. Based on our recent experience of poor responses to high-dose glucocorticoids and plasma exchanges in ICI-related myelitis1 and on the marked IL-6 elevation in the CSF, a second-line treatment with the anti-IL-6-receptor tocilizumab (8 mg/kg IV every 4 weeks) was started, 14 days after symptom onset. To broaden the inhibition of cytokine signaling, the Janus kinase (JAK) inhibitor ruxolitinib (25 mg orally, twice daily) was initiated (Figure 1A). JAKs are crucial enzymes in downstream signaling of type I and type II cytokine receptors including IL-6R, being required for the activation of mitogen-activated protein kinase, phosphatidylinositol-4,5-bisphosphate-3-kinase, and signal transducer and activator of transcription pathways. Ruxolitinib was also added to prevent a possible initial worsening of inflammation due to the expected transient tocilizumab-induced elevation of IL-6 and consequent signal transduction activation.2

Five days after starting second-line treatment, the patient started improving (Video 1), showing a parallel radiologic amelioration (Figure 1, D and E), a resolution of CSF inflammation, and a dramatic decrease of CSF IL-6 levels (Figure 1A). Measurement of drug levels, 2 weeks after starting second-line treatment, confirmed that both compounds were present in the CSF at therapeutic concentrations (tocilizumab: serum 21 μg/mL, CSF 6 μg/mL and ruxolitinib: serum 138 ng/mL, CSF 12.6 ng/mL). At that time, protein levels in the CSF were 0.55 g/dL, reflecting a very mild blood-brain barrier damage. Tocilizumab was continued for a total of 3 infusions, until a steady decrease of IL-6 in the CSF was observed, whereas ruxolitinib was discontinued after 3 weeks because of grade 3 anemia.

Video 1

The patient five days after the start of the second-line therapy with tocilizumab plus ruxolitinib, regaining legs movement.Download Supplementary Video 1 via http://dx.doi.org/10.1212/001073_Video_1

At 3 months from myelitis onset, the patient was able to walk with support (Video 2) and constantly improve with physical therapy. At the last follow-up, 9 months from onset, he could walk independently without limitations of the walking perimeter (Video 3), and he was able to resume his work, although he still had mild sensory ataxia and a bladder and bowel dysfunction. Spinal MRI showed a substantial regression of previously reported abnormalities. Oncologic re-evaluation showed persistent partial response with no progression of his metastatic melanoma, and he remained on simple surveillance.

Video 2

The patient three months after the start of the second-line therapy, able to walk with aid.Download Supplementary Video 2 via http://dx.doi.org/10.1212/001073_Video_2

Video 3

The patient at last follow up, nine months after the start of the second-line therapy, able to walk independently.Download Supplementary Video 3 via http://dx.doi.org/10.1212/001073_Video_3

The present case, recently included in a series of longitudinally extensive myelitis,1 underscores the value of personalized treatment approaches in severe neurologic irAEs, as recently proposed for other irAEs.3,4 In this case, the marked increase of CSF IL-6 suggested the potential value of IL-6-receptor inhibition. Tocilizumab has recently demonstrated its efficacy in patients with ICI-related cerebritis5 and other non-ICI-related CNS inflammatory conditions, such as neuromyelitis optica spectrum disorder (NMOSD).6 Similarly, ruxolitinib was also effective in a patient with severe NMOSD.7 In this study, we demonstrated that both agents reach therapeutic concentrations in the CNS and might be effectively used to treat severe, corticoresistant neurologic irAEs. Nevertheless, we acknowledge the limitations of single-case reporting; we cannot exclude that glucocorticoids and plasma exchange, or a naturally improving course of the disease itself, could have played a role in clinical and biological improvement. Our report is hypothesis generating, and further studies are needed. Cytokine measurement in serum and CSF might help to select patients that would benefit from cytokine blockade.

Data Availability

Further anonymized data will be made available upon reasonable request.

Study Funding

The authors report no targeted funding.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • ↵* These authors contributed equally to this work.

  • The Article Processing Charge was funded by the authors.

  • Received February 28, 2021.
  • Accepted in final form June 15, 2021.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Picca A,
    2. Berzero G,
    3. Bihan K, et al
    . Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e967.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Teachey DT,
    2. Lacey SF,
    3. Shaw PA, et al
    . Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-679.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Martins F,
    2. Sykiotis GP,
    3. Maillard M, et al
    . New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20(1):e54-e64.
    OpenUrlPubMed
  4. 4.↵
    1. Esfahani K,
    2. Elkrief A,
    3. Calabrese C, et al
    . Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504-515.
    OpenUrlPubMed
  5. 5.↵
    1. Stroud CR,
    2. Hegde A,
    3. Cherry C, et al
    . Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551-557.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Zhang C,
    2. Zhang M,
    3. Qiu W, et al
    . Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401.
    OpenUrlCrossRef
  7. 7.↵
    1. Hodecker SC,
    2. Stellmann JP,
    3. Rosenkranz SC, et al
    . Ruxolitinib treatment in a patient with neuromyelitis optica: a case report. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e328.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Data Availability
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Oncology
  • All Immunology
  • Autoimmune diseases
  • Cerebrospinal Fluid
  • Transverse myelitis

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Neurologic autoimmunity and immune checkpoint inhibitors
    Autoantibody profiles and outcomes
    Elia Sechi, Svetomir N. Markovic, Andrew McKeon et al.
    Neurology, August 13, 2020
  • Article
    Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
    Divyanshu Dubey, William S. David, Anthony A. Amato et al.
    Neurology, August 12, 2019
  • Article
    Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors
    Martha Nowosielski, Franziska Di Pauli, Sarah Iglseder et al.
    Neurology: Neuroimmunology & Neuroinflammation, May 27, 2020
  • Article
    Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
    Alberto Picca, Giulia Berzero, Kevin Bihan et al.
    Neurology: Neuroimmunology & Neuroinflammation, February 26, 2021
Neurology - Neuroimmunology Neuroinflammation: 10 (6)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise